Odyssey Group International (ODYY) 10-K/A 13 Nov 20 2019 FY Annual report (amended) Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Jul. 31, 2019	Oct. 23, 2019	Jan. 31, 2019
Document And Entity Information
Entity Registrant Name	Odyssey Group International, Inc.
Entity Central Index Key	0001626644
Document Type	10-K/A
Document Period End Date	Jul. 31, 2019
Amendment Flag	true
Amendment Description	Restated Financials
Current Fiscal Year End Date	--07-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Non-accelerated Filer
Entity Public Float			$ 25,735,000
Entity Common Stock, Shares Outstanding		86,990,400
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2019
Entity Small Business	true
Entity Emerging Growth	false
Entity Shell Company	false
Entity Interactive data current	Yes
Entity File Number	333-200785
Entity Incorporation State Country Code	NV

Balance Sheets

Balance Sheets - USD ($)	Jul. 31, 2019	Jul. 31, 2018
Current Assets:
Cash and cash equivalents	$ 167,095	$ 390
Prepaid expenses	302,833	0
Loan receivable	50,000	0
Total Current Assets	519,928	390
Property and equipment, net	1,517	2,069
Intangible assets	15,000	25,000
Total Assets	536,445	27,459
Current liabilities:
Accounts payable	47,743	26,691
Accrued wages	297,547	188,500
Note payable, including accrued interest	784,913	631,645
Total liabilities	1,130,203	846,836
Stockholders' equity (deficiency):
Preferred stock, $.001 par value; 100,000,000 shares authorized, no shares issued or outstanding	0	0
Common stock, $.001 par value; 500,000,000 shares authorized with 86,990,400 and 61,414,000 issued and outstanding	86,990	61,414
Additional paid-in capital	23,821,124	192,086
Deficit	(24,501,872)	(1,072,877)
Total stockholders' equity (deficiency)	(593,758)	(819,377)
Total Liabilities and stockholders' equity (deficiency)	$ 536,445	$ 27,459

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Jul. 31, 2019	Jul. 31, 2018
Statement of Financial Position [Abstract]
Preferred Stock, Par Value	$ 0.001	$ .001
Preferred Stock, Shares Authorized	100,000,000	100,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Par Value	$ 0.001	$ .001
Common Stock, Shares Authorized	500,000,000	500,000,000
Common Stock, Shares Issued	86,990,400	61,414,000
Common Stock, Shares Outstanding	86,990,400	61,414,000

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Jul. 31, 2019	Jul. 31, 2018
Income Statement [Abstract]
Revenues	$ 0	$ 0
Cost of goods sold	0	0
Gross profit	0	0
General and administrative expenses	23,358,713	288,995
Impairment loss	0	131,447
Loss from operations	(23,358,713)	(420,442)
Interest expense	(70,282)	(62,673)
Net loss	$ (23,428,995)	$ (483,115)
Basic net loss per share:	$ (0.34)	$ 0
Weighted average number of shares	69,898,436	117,128,060

Statements of Stockholders' Equ

Statements of Stockholders' Equity (Deficiency) - USD ($)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Beginning balance, shares at Jul. 31, 2017	114,839,600
Beginning balance, value at Jul. 31, 2017	$ 114,840	$ 55,060	$ (589,762)	$ (419,862)
Debt converted to common stock, shares	1,574,000
Debt converted to common stock, value	$ 1,574	32,026	0	33,600
Common stock issued for services, shares	5,000,000
Common stock issued for services, value	$ 5,000	45,000	0	50,000
Common stock restructure, shares	(60,000,000)
Common stock restructure, value	$ (60,000)	60,000		0
Net loss (Restated)			(483,115)	(483,115)
Ending balance, shares at Jul. 31, 2018	61,414,000
Ending balance, value (Restated) at Jul. 31, 2018	$ 61,414	192,086	(1,072,877)	(819,377)
Note payable converted to common stock, shares	2,531,400
Note payable converted to common stock, value	$ 2,531	22,783		25,314
Common stock issued for services, shares	321,000
Common stock issued for services, value	$ 321	$ 331,929		$ 332,250
Common stock issued for compensation, shares	4,720,000
Common stock issued for compensation, value	4,720	67,280		72,000
Common stock issued for acquisition of in-process research and development, shares	18,004,000
Common stock issued for acquisition of in-process research and development, value	$ 18,004	$ 22,486,996		$ 22,505,000
Common stock options issued for acqusition of in-process research and development		506,400		506,400
Warrants issued in connection with convertible notes		13,075		13,075
Beneficial conversion feature related to convertible notes		200,575		200,575
Net loss (Restated)			(23,428,995)	(23,428,995)
Ending balance, shares at Jul. 31, 2019	86,990,400
Ending balance, value (Restated) at Jul. 31, 2019	$ 86,990	$ 23,821,124	$ (24,501,872)	$ (593,758)

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Jul. 31, 2019	Jul. 31, 2018
Operating activities
Net loss	$ (23,428,995)	$ (483,115)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	10,551	10,551
Impairment loss	0	131,447
custom:CommonStockForInprocessResearchAndDevelopment	23,011,400	0
Stock based payment expense for consulting and compensation	101,417	0
Debt discount	408	0
Changes in operating assets and liabilities:
Increase in accounts payable	21,053	47,882
Increase in accrued wages	109,047	84,500
Increase in accrued interest	70,282	62,673
Net cash used in operating activities	(104,837)	(146,062)
Investing activities
Net cash used in investing activities	0	0
Financing activities
Proceeds from notes payable	271,542	133,026
Net cash provided by financing activities	271,542	133,026
Net change in cash and cash equivalents	166,705	(13,036)
Cash and cash equivalents, beginning of year	390	13,426
Cash and cash equivalents, end of year	167,095	390
Noncash transactions:
Common stock issued for consulting services	332,250	50,000
Benefical conversion feature related to convertible notes	213,650	0
Accounts payable transferred to note payable	25,314	15,000
Debt converted to Common Stock	0	60,000
Stock restructure- Common stock	$ 0	$ 36,500

1. Nature of Operations

1. Nature of Operations	12 Months Ended
	Jul. 31, 2019
Accounting Policies [Abstract]
Nature of Operations	1. Nature of Operations The corporate mission is to create or acquire distinct assets, intellectual property, and technologies with an emphasis on acquisition targets that generate positive cash flow. Our business model is to develop or acquire medical related products, engage third parties to manufacture such products and then distribute the products through various distribution channels, including third parties. The Company has made significant investments in three different life saving technologies; the CardioMap® heart monitoring and screening device, the Save a Life choking rescue device and a unique neurosteroid drug compound intended to treat rare brain disorders. We intend to acquire other technologies and assets and plan to be a trans-disciplinary product development company involved in the discovery, development and commercialization of products and technologies that may be applied over various medical markets. We intend to license, improve and/or develop our products and identify and select distribution channels. We intend to establish agreements with distributors to get products to market quickly as well as to undertake and engage in our own direct marketing efforts. We will determine the most effective method of distribution for each unique product that we include in our portfolio. We intend to engage third party research and development firms who specialize in the creation of our products to assist us in the development of our own products We intend to apply for trademarks and patents once we have developed proprietary products. We are not currently selling or marketing any products, as our product is in late stage development and Food and Drug Administration ("FDA") clearance or approval to market the product will be required in order to sell in the United States.

2. Restatement for Correction o

2. Restatement for Correction of an Error	12 Months Ended
	Jul. 31, 2019
Accounting Changes and Error Corrections [Abstract]
Restatement for Correction of an Error	2. Restatement for Correction of an Error The Company has determined that the research and developments costs previously capitalized in the intangible assets should be recognized as research and development expenses to be in compliance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 730 Research and Development (ASC 730-10-25-2(c)). Pursuant to ASC 730-10-25-2(c), intangibles purchased from others for use in particular research and development projects and that have no alternative future use, in research and development or otherwise, represent costs of research and development as acquired, and therefore are expensed when incurred. During the year ended July 31, 2019, the Company acquired and capitalized the following intangible assets. The Company acquired the patent related to the exclusive license and distribution rights of the CardioMap®, which is intended to be an advanced technology for early non-invasive testing for heart disease. The license to the patent and product distribution rights were being amortized over the life of the underlying patent. The acquisition cost of $18.75 million and was valued at the fair market value of $1.25 per share for the stock granted on the date of acquisition. The Company acquired the intellectual property, know-how and patents for an anti-choking, life-saving medical device from Dr. James De Luca, inventor and Murdock Capital Partners. The asset was valued at $675,400, which includes the fair market value of $1.25 per share for the stock granted on the date of acquisition, as well as stock options granted valued at $0.84 per share based upon the Black-Scholes valuation model and a onetime cash payment totaling $250,000 that will be paid upon FDA clearance of the product. The payment was recorded as a contingent liability and with a fair market value of $144,000. The Company acquired an interest in the patented chemical compound for a neurosteroid as part of an agreement with Prevacus, Inc. The acquisition cost was $3.73 million and was being amortized over the life of the patent. The asset was valued at the fair market value of $1.25 per share for the stock granted on the date of acquisition. The intellectual property, know-how and patents were being amortized over the life of the patents. In the Affected Reports, the Company recorded such development cost as intangible assets. The adjustments required to correct the foregoing treatment of such costs resulted in a non-cash increase in research & development expense and a decrease of intangible assets of $23,011,400 and an increase in accumulated amortization and a decrease in amortization expense of $30,830. For the fiscal year ended July 31, 2019, general and administrative expenses increased $22,980,570 and net intangible assets decreased $23,124,570 and contingent liability decreased by $144,000. In addition to the restatement of the financial statements, certain information within the following notes to the financial statements have been restated to reflect the correction of a misstatement discussed above as well as to add disclosure language as appropriate: Note 3. Summary of Significant Accounting Policies Note 5. Intangible Assets Note 10. Income Taxes Note 11. Going Concern Note 12. Related Party Transactions The financial statement misstatements reflected in the table below did not impact cash flows from operations, investing, or financing activities in the Company’s statements of cash flows for any period previously presented. Comparison of restated financial statements to financial statements as previously reported The following tables compare the Company’s previously issued Balance Sheets, Statement of Operations, Statement of Stockholders’ Equity (Deficiency), and Statement of Cash Flows as and for the year ended of July 31, 2019 and for the corresponding restated financial statements for that year end. Odyssey Group International, Inc. Balance Sheets Balance Sheet As Previously Reported Adjustments As Restated Assets Current assets: Cash and cash equivalents $ 167,095 $ – $ 167,095 Prepaid expenses 302,833 – 302,833 Loan receivable 50,000 – 50,000 Total current assets 519,928 – 519,928 Property and equipment, net 1,517 – 1,517 Intangible assets - patents & license distribution rights 23,139,570 (23,124,570 ) 15,000 Total assets $ 23,661,015 $ (23,124,570 ) $ 536,445 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 47,743 $ – $ 47,743 Accrued wages 297,547 – 297,547 Contingent liability 144,000 (144,000 ) – Notes payable, including accrued interest 784,913 – 784,913 Total liabilities 1,274,203 (144,000 ) 1,130,203 Stockholders' equity (deficiency): Preferred stock, $.001 par value; 100,000,000 shares authorized, no shares issued or outstanding – – – Common stock, $.001 par value; 500,000,000 shares authorized with 86,990,400 and 61,414,000 issued and outstanding 86,990 – 86,990 Additional paid-in capital 23,821,124 – 23,821,124 Deficit (1,521,302 ) (22,980,570 ) (24,501,872 ) Total stockholders’ equity (deficiency) 22,386,812 (22,980,570 ) (593,758 ) Total liabilities and stockholders’ equity (deficiency) $ 23,661,015 $ (23,124,570 ) $ 536,445 Odyssey Group International, Inc. Statements of Operations July 31, 2019 As Previously Reported Adjustments As Restated Revenues – – – Costs of goods sold – – – Gross profit – – – General and administrative expense $ 378,143 $ 22,980,570 $ 23,358,713 Loss from operations (378,143 ) (22,980,570 ) (23,358,713 ) Interest expense (70,282 ) – (70,282 ) Net loss $ (448,425 ) $ (22,980,570 ) $ (23,428,995 ) Basic net loss per share: (0.01 ) $ (0.33 ) $ (0.34 ) Weighted average number of shares $ 69,898,436 69,898,436 69,898,436 Odyssey Group International, Inc. Statements of Stockholders’ Equity (Deficiency) For the Years Ended July 31, 2019 and 2018 Common Stock Additional Paid-In Total Equity Shares Dollars Capital Deficit (Deficiency) Balances July 31, 2017 114,839,600 $ 114,840 $ 55,060 $ (589,762 ) $ (419,862 ) Debt converted to common stock 1,574,400 1,574 32,026 – 33,600 Common stock issued for services 5,000,000 5,000 45,000 – 50,000 Common stock restructure (60,000,000 ) (60,000 ) 60,000 – – Net loss – – – (483,115 ) (483,115 ) Balances July 31, 2018 61,414,000 $ 61,414 $ 192,086 $ (1,072,877 ) $ (819,377 ) Note payable converted to common stock 2,531,400 2,531 22,783 – 25,314 Common stock issued for services 321,000 321 331,929 – 332,250 Common stock issued for compensation 4,720,000 4,720 67,280 – 72,000 Common stock issued for acquisition of in-process research and development 18,004,000 18,004 22,486,996 – 22,505,000 Common stock options issued for acquisition of in-process research and development – – 506,400 – 506,400 Warrants issued in connection with convertible notes – – 13,075 – 13,075 Beneficial conversion feature related to convertible notes – – 200,575 – 200,575 Net loss - (Restated) – – – (23,428,995 ) (23,428,995 ) Balances July 31, 2019 (Restated) 86,990,400 $ 86,990 $ 23,821,124 $ (24,501,872 ) $ (593,758 ) Odyssey Group International, Inc. Statements of Cash Flows Year Ended July 31, 2019 As Previously Reported Adjustments As Restated Operating activities Net loss $ (448,425 ) $ (22,980,570 ) $ (23,428,995 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization expense 41,381 (30,830 ) 10,551 Common stock for in-process research and development – 23,011,400 23,011,400 Stock based payment expense for consulting and compensation 101,417 – 101,417 Debt discount 408 – 408 Changes in operating assets and liabilities: Increase in accounts payable 21,053 – 21,053 Increase in accrued wages 109,047 – 109,047 Increase in accrued interest 70,282 – 70,282 Net cash used in operating activities (104,837 ) – (104,837 ) Financing activities Proceeds from note payable 271,542 – 271,542 Net cash provided by financing activities 271,542 – 271,542 Net change in cash and cash equivalents 166,705 – 166,705 Cash and cash equivalents, beginning of year 390 – 390 Cash and cash equivalents, end of year $ 167,095 – $ 167,095 Noncash Investing and Financing Activities Common stock issued for acquisition of intangible assets $ 22,505,000 $ (22,505,000 ) – Common stock issued for consulting services 332,250 – 332,250 Beneficial conversion feature related to convertible notes 213,650 – 332,250 Contingency liability related to acquisition of intangible assets 144,000 (144,000 ) – Debt converted to common stock 25,314 – 23,314

3. Summary of Significant Accou

3. Summary of Significant Accounting Policies	12 Months Ended
	Jul. 31, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	3. Summary of Significant Accounting Policies Use of estimates The preparation of financial statements in conformity with Generally Accepted Accounting Principles (“GAAP”) generally requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Basis of accounting The Company has not elected to adopt the option available under GAAP to measure any of its eligible financial instruments or other items at fair value. Accordingly, the Company measures all of its assets and liabilities on the historical cost basis of accounting unless otherwise required by GAAP. Accounts receivable Accounts receivable are carried at original invoice amount less an estimated allowance for doubtful accounts, if deemed necessary by management. An allowance for doubtful accounts is based on a review of all outstanding amounts on a monthly basis. Management determines the allowance for doubtful accounts, if any, by identifying troubled accounts and by using historical experience applied to an aging of accounts. Property and equipment, net Property and equipment is stated at cost less accumulated depreciation. Depreciation is recorded on a straight-line basis over the estimated useful lives of the assets. For the year ended July 31, 2019 and 2018 the Company recognized depreciation expense of $552. Beneficial Conversion Feature of convertible notes payable The Beneficial Conversion Feature ("BCF") of a convertible note is normally characterized as the convertible portion or feature of certain notes payable that provide a rate of conversion that is below market value or in-the-money when issued. The Company records a BCF related to the issuance of a convertible note when issued and also records the estimated fair value of any warrants issued with those convertible notes. Beneficial conversion features that are contingent upon the occurrence of a future event are recorded upon the occurrence of the event. The BCF of a convertible note is measured by allocating a portion of the note's proceeds to the warrants, if applicable, and as a reduction of the carrying amount of the convertible note equal to the intrinsic value of the conversion feature, both of which are credited to additional paid-in-capital. The value of the proceeds received from a convertible note is then allocated between the conversion features and warrants on an allocated fair value basis. The allocated fair value is recorded in the financial statements as a debt discount (premium) from the face amount of the note and such discount is amortized over the expected term of the convertible note (or to the conversion date of the note, if sooner) and is charged to interest expense. Net loss per share Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. No fully diluted loss per share is presented, because it would be anti-dilutive. Revenue recognition The Company recognizes revenue when control is transferred to the customer. For products sold through direct sales representatives, control is transferred upon shipment or upon delivery, based on the contract terms and legal requirements. Payment terms vary depending on the country of sale, type of customer, and type of product. If a contract contains more than one performance obligation, the transaction price is allocated to each performance obligation based on relative standalone selling price. Shipping and handling is treated as a fulfillment activity rather than a promised service, and therefore, is not considered a performance obligation. Taxes assessed by a governmental authority that are both imposed on, and concurrent with, a specific revenue producing transaction and collected by the Company from customers (for example, sales, use, value added, and some excise taxes) are not included in revenue. For contracts that have an original duration of one year or less, the Company uses the practical expedient applicable to such contracts and does not adjust the transaction price for the time value of money. We are not currently selling or marketing any products, as our product is in late stage development and FDA clearance to market the product will be required in order to sell in the United States. Research and development expense Research and development expense is expensed in the period when incurred. For the year ended July 31, 2019 and 2018, the Company incurred research and development expense of $23,011,400 and zero, respectively. Income taxes Income taxes are accounted for based upon an asset and liability approach. Accordingly, deferred tax assets and liabilities arise from the difference between the tax basis of an asset or liability and its reported amount in the financial statements. Deferred tax amounts are determined using the tax rates expected to be in effect when the taxes will actually be paid or refunds received, as provided under currently enacted tax law. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense or benefit is the tax payable or refundable, respectively, for the period plus or minus the change in deferred tax assets and liabilities during the period. Accounting guidance requires the recognition of a financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company believes its income tax filing positions and deductions will be sustained upon examination and accordingly, no reserves, or related accruals for interest and penalties have been recorded at July 31, 2019 and 2018. The Company recognizes interest and penalties on unrecognized tax benefits as well as interest received from favorable tax settlements within income tax expense. On December 22, 2017, the President of the United States signed and enacted into law H.R. 1 (the “Tax Reform Law”). The Tax Reform Law, effective for tax years beginning on or after January 1, 2018, except for certain provisions, resulted in significant changes to existing United States tax law, including various provisions that are expected to impact the Company. The Tax Reform Law reduces the federal corporate tax rate from 34% to 21% effective January 1, 2018. The Company analyzed the provisions of the Tax Reform Law to assess the impact on the Company’s financial statements and determined it had no material impact.

4. Impact of New Accounting Pro

4. Impact of New Accounting Pronouncements	12 Months Ended
	Jul. 31, 2019
Accounting Changes and Error Corrections [Abstract]
Impact of New Accounting Pronouncements	4. Impact of New Accounting Pronouncements Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”), in the form of Accounting Standards Updates (“ASUs”), to the FASB’s Accounting Standards Codification. The Company considers the applicability and impact of all ASUs. The FASB issued ASU 2017-11, Earnings Per Share (Topic 260) effective for annual reporting periods beginning after December 15, 2018. The amendments update the change in the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. This new guidance is effective for interim and annual reporting periods beginning after December 15, 2018 and interim periods, with early adoption permitted. The Company will adopt the standard as of August 1, 2019 and does not expect the adoption to have a material impact on the Company’s financial statements and disclosures. The FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting, effective for annual reporting periods beginning after December 15, 2017 adopting this standard on its financial statements. The ASU amends the scope of modification accounting for share-based payment arrangements, provides guidance on the types of changes to the terms or conditions of share-based payment awards to which an entity would be required to apply modification accounting. The new guidance will allow companies to make certain changes to awards without accounting for them as modifications. It does not change the accounting for modifications. The new guidance will be applied prospectively to awards modified on or after the adoption date. This new guidance is effective for interim and annual reporting periods beginning after December 15, 2018. The Company will adopt the standard as of August 1, 2019 and does not expect the adoption to have a material impact on the Company’s financial statements and disclosures. The FASB issued ASU 2016-02, Leases (Topic 842), which is intended to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. The guidance requires lessees and lessors to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. ASU 2016-02 is effective for annual periods beginning after December 15, 2018, including interim periods within those annual periods, with early adoption permitted. The Company will adopt the standard as of August 1, 2019 and does not expect the adoption to have a material impact on the Company’s financial statements and disclosures.

5. Intangible Assets

5. Intangible Assets	12 Months Ended
	Jul. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	5. Intangible Assets FASB ASC 820, "Fair Value Measurements and Disclosures", establishes a framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under FASB ASC 820 are described as follows: Level 1 – Observable inputs, such as unadjusted quoted prices in active markets, for substantially identical assets and liabilities. Level 2 – Observable inputs other than quoted prices within Level 1 for similar assets and liabilities. These include quoted prices for similar assets and liabilities in active markets, quoted prices for identical assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data. If the asset or liability has a specified or contractual term, the input must be observable for substantially the full term of the asset or liability. Level 3 – Unobservable inputs that are supported by little or no market activity, generally requiring a significant amount of judgment by management. The assets or liabilities fair value measurement level within the fair value hierarchy is based on the lowest level. The methods described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Further, although the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

6. Notes Payable

6. Notes Payable	12 Months Ended
	Jul. 31, 2019
Debt Disclosure [Abstract]
Notes Payable	6. Notes Payable As of July 31, 2019, the Company has a note payable that is subject to periodic payments that come due based on sales. The note fully matures in January 2020, bears interest at 12.5% annually, and the remaining unpaid balance is convertible upon maturity at the holder’s option into shares of common stock at a conversion price fixed at $0.01 per share. As of July 31, 2019, the note has a balance of $747,608. Because the conversion feature does not meet the criteria for characterization as a beneficial conversion feature, no portion of the proceeds from the issuance of the note was accounted for as attributable to the conversion feature. This note was amended on February 1, 2018, where the debt holder agreed to convert portions of its loan pari passu with any new investment raise of $500,000 or more. Furthermore, the debt holder was issued a common stock warrant for 4 million shares at $0.25 per share with an expiration date of 90 days after the issuance, as consideration to the debt holder to agree to begin to convert portions of its loan to common stock pari passu with a new offering raise of investment at a minimum of $500,000. As of July 31, 2019, these warrants expired. As of July 31, 2019, the Company has three additional convertible debt notes outstanding. The notes bear interest at 7.0% annually and the entire outstanding principal amount, together with accrued interest shall become due and payable on the date that is one (1) year from the date of issuance, unless before such date, is converted into shares of capital stock of the Company. At the option of the holder, the principal amount of the notes and any accrued interest may be converted into shares of common stock at a conversion price of $1.00 per share or at a 10% discount to the closing price on the day of conversion, but not lower than $0.50 per share. At maturity, and subject to a trickle out agreement, the Company shall have the right to either pay off the loan and any interest accrued or convert the loan amount and any interest into shares of common stock. The debt holders were issued a common stock warrant equal to 10% of the note with a price of $1.50 per share and a term for one year from the investment date. At July 31, 2019, the notes have a balance of $37,305. Because the conversion feature met the criteria for characterization as a beneficial conversion feature, a portion of the proceeds, including warrants, of $213,650 from the issuance of the notes are accounted for as attributable to the conversion feature.

7. Fair Value Measurements

7. Fair Value Measurements	12 Months Ended
	Jul. 31, 2019
Fair Value Disclosures [Abstract]
Fair Value Measurements	7. Fair Value Measurements The carrying values of cash, the note receivable, and notes payable approximate their estimated fair values because of the short-term nature of these instruments.

8. Common Stock

8. Common Stock	12 Months Ended
	Jul. 31, 2019
Equity [Abstract]
Common Stock	8. Common Stock For the year ended July 31, 2018, the Company’s Board approved the return of 60 million shares from the founding common stockholders. On December 11, 2018, the Company amended the employment agreement of J. Michael Redmond to further document and incorporate the transition of the control of the Green Energy Alternatives stock. In the amendment, the Company agrees to issue Mr. Redmond a total of 10 million shares of the Company’s common stock. At least 4.7 million stock grants were granted to Mr. Redmond from the Company, and 5.3 million shares have been assigned to Mr. Redmond through control of Green Energy Alternatives, LLC. The Company recognized $47,000 of compensation expense related to the 4.7 million shares granted, with an estimated fair value of $0.01 per share, for the year ended July 31, 2019. On January 9, 2019, Vivakor, Inc. (“Vivakor”) gave written notice to the Company effecting a conversion of $25,314 of convertible debt into 2,531,400 shares of Common Stock of the Company, issued to Vivakor pursuant to the Master Revolving Note, dated as of January 4, 2017, and amended as of February 1, 2018, by and between the Company and Vivakor. On April 17, 2019, the Company entered into an agreement for consulting services to be provided through April 2020. The Company granted the consultant 100,000 shares of the Company’s common stock. On May 22, 2019, the Company entered into employment agreements for two part-time employees. The Company granted the employees 10,000 shares each of the Company’s common stock. On March 22, 2019, April 17, 2019, June 1, 2019, and July 26, 2019, the Company entered into agreements for consulting services for the next 12 months. The Company granted the consultants a total of 305,000 shares of the Company’s common stock. On June 27, 2019, Odyssey entered into a Definitive Agreement with Prevacus to form a Joint Venture relating to the development of a neurosteroid for treating two orphan disorders, ALS and Niemann Picks disease. Prevacus contributed to the JV, the chemical compound and Odyssey is be responsible for funding the JV through Phase One clinical trials. The JV company will own the patents. Each party will own the JV company equally. In addition to the JV, the two companies have entered into a share exchange agreement whereby Prevacus will receive three million shares of Odyssey common stock and Odyssey will receive one million shares of Prevacus stock. The chemical compound for the neurosteroid being developed has issued patents, and as consideration for the patented compound, Odyssey issued Prevacus two million shares of its common stock. As part of the Agreement, Dr. Jacob Vanlandingham Ph.D., CEO of Prevacus, was issued one million shares of the Company’s common stock. The Company allocated 984,000 shares to the acquisition of the patent and 16,000 shares were allocated to Dr. Vanlandingham as a Director of the Company. On June 27, 2019, Odyssey entered into a Definitive Agreement with Dr. James De Luca, inventor and Murdock Capital Partners, advisors to De Luca, to acquire the intellectual property, know-how and patents for a life-saving medical device currently in development. The Company acquired intellectual property rights, namely, United States Letters Patent No. 7,559,921, entitled “Device for Removing a Lodged Mass” which issued on July 14, 2009 and which was reissued on June 2, 2015 and received U.S. Reissue Patent No. Re 45,535 and United States Patent Number 8,454,624 also entitled “Device for Removing a Lodged Mass” which was issued on June 4, 2013. As consideration for the patent and intellectual property, the Company granted stock options totaling 600,000 shares of the Company’s stock, vesting on certain milestones. The options will be split between De Luca and MCP. The Company also granted De Luca, 20,000 common shares. A onetime cash payment totaling $250,000 will be paid to Deluca and MCP upon FDA clearance of the product.

9. Stock Based Compensation

9. Stock Based Compensation	12 Months Ended
	Jul. 31, 2019
Share-based Payment Arrangement [Abstract]
Stock Based Compensation	9. Stock Based Compensation We have not adopted any equity compensation plans. We have entered into an individual compensation plan for Mr. Redmond, for which Mr. Redmond has been granted stock options of 15 million shares at $0.25 per share. The options vest upon achieving the following milestones: 5 million options vest upon each milestone, when the Company obtains revenue of $5 million, $10 million and $15 million. Mr. Redmond cannot sell any of the above stock options for two years from the effective date of the employment agreement or until the Company reaches $10 million in annual revenue, whichever occurs first. The stock option vesting accelerates and becomes immediately exercisable upon the sale, merger or any transaction resulting in the majority (more than 50%) of the Company stock being obtained. The Company has not recorded any expense, as we have not determined that it is probable that the milestones will be achieved.

10. Income Taxes

10. Income Taxes	12 Months Ended
	Jul. 31, 2019
Income Tax Disclosure [Abstract]
Income Taxes	10. Income Taxes We file income tax returns in the U.S. federal jurisdiction and the various states in which we operate. The Company registered with the Franchise Tax Board in the State of California in tax year 2020, but was not required to file a tax return for tax year 2019. The Company’s tax returns are currently not under examination for any year. The Company’s deferred tax assets consist of federal net operating loss carryforwards that expire through the year 2035. The deferred tax assets are net of a 100% valuation allowance as it is more likely than not at this time that the deferred tax assets will not be realized within the carryforward period due to substantial uncertainty as to the Company’s ability to continue as a going concern (Note 11). The following table reconciles the U.S. federal statutory rate to the Company’s effective tax rate: For the year ended July 31, 2019 2018 US federal statutory rates $ 21% $ 21% Valuation allowance (21% ) (21% ) Effective tax rate $ 0% $ 0% The Company’s tax provision (benefit) was as follows: For the year ended July 31, 2019 2018 Current deferred $ 44,900 $ (291,100 ) Increase in valuation allowance (44,900 ) 291,100 Total $ – $ – The Company’s net deferred tax asset as of July 31, 2019 and 2018 is as follows: For the year ended July 31, 2019 2018 Deferred tax asset $ (246,200 ) $ (291,100 ) Valuation allowance 246,200 291,100 Net deferred tax asset $ – $ – As of July 31, 2019, the Company had $821,727 of federal net operating loss carry forwards. These carry forwards, if not used, will begin to expire in 2035. Current or future ownership changes, including issuances of common stock under the terms of the Company’s convertible notes payable may severely limit the future realization of these net operating losses. The Company provides for a valuation allowance when it is more likely than not that they will not realize a portion of the deferred tax assets. The Company has established a valuation allowance against their net deferred tax asset due to the uncertainty that enough taxable income will be generated in those taxing jurisdictions to utilize the assets. Therefore, they have not reflected any benefit of such deferred tax assets in the accompanying financial statements. The Company’s net deferred tax asset and valuation allowance decreased by $44,900 for the year ended July 31, 2019, related to the current year activity. The Company has reviewed all income tax positions taken or that are expected to be taken for all open years and determined that their income tax positions are appropriately stated and supported for all open years. The Company is subject to U.S. federal income tax examinations by tax authorities for years after 2019 due to unexpired net operating loss carryforwards originating in and subsequent to that year. The Company may be subject to income tax examinations for the various taxing authorities which vary by jurisdiction. The Company’s policy is to record interest and penalties associated with unrecognized tax benefits as additional income taxes in the statements of operations. As of July 31, 2019, there were no unrecognized tax benefits, or any tax related interest or penalties. The Company does not have any examinations ongoing. Tax returns for the years 2014 onwards are subject to federal, state or local examinations.

11. Going Concern

11. Going Concern	12 Months Ended
	Jul. 31, 2019
Risks and Uncertainties [Abstract]
Going Concern	11. Going Concern We have a deficit of $24,501,872, as of July 31, 2019. For the foreseeable future, we expect to experience continuing operating losses and negative cash flows from operations as our management executes our current business plan. The cash available at July 31, 2019, may not provide enough working capital to meet our current operating expenses through October 23, 2020, as we continue to accrue overhead expenses. We will need to raise additional capital through a debt financing or equity offering to meet our operating and capital needs. There can be no assurance, however, that we will be successful in our fundraising efforts or that additional funds will be available on acceptable terms, if at all. If we are unable to raise additional capital by October 23, 2020, we will adjust our current business plan. Due to our lack of additional committed capital, recurring losses, negative cash flow and accumulated deficit, there is substantial doubt about the Company’s ability to continue as a going concern.

12. Related Party Transactions

12. Related Party Transactions	12 Months Ended
	Jul. 31, 2019
Related Party Transactions [Abstract]
Related Party Transactions	12. Related Party Transactions The Company has a common officer with Green Energy Alternatives, Inc. As of July 31, 2019, and 2018, Green Energy Alternatives, Inc. held 5.3 million shares of the Company’s common stock. Due to officer During the year ended July 31, 2019, Mr. Redmond, CEO, paid approximately $30,060 of expenses incurred by the Company and the amount is included in accounts payable at July 31, 2019. During the year ended July 31, 2018, there were no expenses incurred by Mr. Redmond, CEO. Accounts Payable Year Ended Year Ended 31-Jul-19 31-Jul-18 Joseph M. Redmond, CEO $ 30,060 $ – Accrued Compensation Total Balance 7/31/2018 $ 80,000 2019 Salary 120,000 Payments (18,462 ) Balance 7/31/2019 $ 181,538 It has been determined that Dr. Vanlandingham is considered a related party due to his affiliation with Prevacus, Inc. as its president and his position on the Board of Directors, as a result of the agreement that was entered into in June 2019. At the time of the agreement and appointment to the Board, he was not a considered a related party. The Company allocated 984,000 shares to the acquisition of the patent and 16,000 shares were allocated to Dr. Vanlandingham as a Director of the Company. His affiliation has been disclosed in filings but not as a related party transaction.

13. Subsequent Events

13. Subsequent Events	12 Months Ended
	Jul. 31, 2019
Subsequent Events [Abstract]
Subsequent Events	13. Subsequent Events We have evaluated subsequent events and, except for the transaction described below, there were no other events relative to the financial statements that require additional disclosure. On August 6, 2019, the Company entered into a convertible note payable for $100,000. The notes bear interest at 7.0% annually and mature automatically. The entire outstanding principal amount, together with accrued interest shall become due and payable on the date that is one (1) year from the date of issuance, unless converted into shares of capital stock of the Company. Warrants equal to 10% of the shares purchased with a price of $1.50 per share were issued to the note holders. The price of the warrant is $1.50 per share and the term is for one year from the investment date. On August 15, 2019, the Company amended its agreement with its financial consultant to included monthly payments of $5,000 and 200,000 stock options to be granted stock in accordance with the mutual agreement of the Board’s compensation committee. On August 20, 2019, the Company entered into a consulting agreement for research and development associated with the CardioMap®. The consultant will receive monthly payments of $5,000 and 2.0 million stock options, vesting upon certain milestone achievements. On August 28, 2019, Jeff Conroy joined the Board of Odyssey as an independent director. Mr. Conroy is an operating and business development executive with over 30 years in the life science industry across therapeutics and medical devices. Mr. Conroy is the Chairman & CEO of Embody, a DARPA-funded medical device company developing regenerative implants for tendon and ligament repair. Since 2012, he has served as the Head of Corporate Development for Especificos Stendhal S.A. de C.V., a Latin American specialty pharmaceutical company. He is the Managing Director of Windward Investments - structuring licensing partnerships for life science companies. Mr. Conroy is an independent director of Cingulate Therapeutics, a CNS company developing ADHD therapeutics. Mr. Conroy holds a B.S. in Business Administration from Providence College. As Director, Mr. Conroy shall be compensated with stock in accordance with the mutual agreement of the Board’s compensation committee. On September 20, 2019, Jerry Casey joined the Board of Odyssey as an independent director. Jerry Casey has been a leader in the life science industry for over 30 years. Enjoying a long tenure as a senior executive at Genzyme Corporation, Mr. Casey was the driver behind Genzyme’s commercial success in the diagnostics arena, building a $175 million business which Genzyme sold to Japan-based Sekisui Chemical in 2011. Mr. Casey became the President and Chief Operating Officer of the new entity, Sekisui Diagnostics, LLC, until the end of 2014. Since leaving the company, Mr. Casey has been actively involved in several life sciences ventures, both as an advisor and an investor, while serving on multiple Boards. As Director, Mr. Casey shall be compensated with stock in accordance with the mutual agreement of the Board’s compensation committee. On October 3, 2019, the Company and Prevacus, Inc. amended the Master Agreement for a Joint Venture and Intellectual Property Purchase Agreement, dated June 26, 2019, to extend the timing of the formation of the Joint Venture to December 31, 2019. On October 23, 2019, John Gandolfo joined the Board of Odyssey as an independent director and has been elected chair of the audit committee. Mr. Gandolfo has approximately 30 years of experience as a chief financial officer of multiple rapidly growing private and publicly held companies with a primary focus in the life sciences, healthcare and medical device areas. Mr. Gandolfo has had direct responsibility over capital raising, including five public offerings, financial management, mergers and acquisition transactions and SEC reporting throughout his professional career. Mr. Gandolfo is currently Chief Financial Officer of Eyenovia, Inc., a late-stage ophthalmic biopharmaceutical company. Mr. Gandolfo was Chief Financial Officer of Xtant Medical Holdings, Inc. from July 2010 through September 2017. He served as the Chief Financial Officer for Progenitor Cell Therapy LLC from January 2009 to June 2010. Prior to joining Progenitor, Mr. Gandolfo served as the Chief Financial Officer of Power Medical Interventions, Inc. from January 2007 to January 2009. Mr. Gandolfo was the Chief Financial Officer of Bioject Medical Technologies, Inc. He was also the Chief Financial Officer of Capital Access Network, Inc, from 2000 through September 2001, and Xceed, Inc. from 1999 to 2000. From 1994 to 1999, Mr. Gandolfo was Chief Financial Officer and Chief Operating Officer of Impath, Inc. From 1987 through 1994, he was Chief Financial Officer of Medical Resources, Inc. Mr. Gandolfo received his B.A. in business administration from Rutgers University. As Director, Mr. Gandolfo shall be compensated with stock in accordance with the mutual agreement of the Board’s compensation committee.

3. Summary of Significant Acc_2

3. Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Jul. 31, 2019
Accounting Policies [Abstract]
Use of estimates	Use of estimates The preparation of financial statements in conformity with Generally Accepted Accounting Principles (“GAAP”) generally requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.
Basis of accounting	Basis of accounting The Company has not elected to adopt the option available under GAAP to measure any of its eligible financial instruments or other items at fair value. Accordingly, the Company measures all of its assets and liabilities on the historical cost basis of accounting unless otherwise required by GAAP.
Accounts Receivable	Accounts receivable Accounts receivable are carried at original invoice amount less an estimated allowance for doubtful accounts, if deemed necessary by management. An allowance for doubtful accounts is based on a review of all outstanding amounts on a monthly basis. Management determines the allowance for doubtful accounts, if any, by identifying troubled accounts and by using historical experience applied to an aging of accounts.
Property and Equipment, Net	Property and equipment, net Property and equipment is stated at cost less accumulated depreciation. Depreciation is recorded on a straight-line basis over the estimated useful lives of the assets. For the year ended July 31, 2019 and 2018 the Company recognized depreciation expense of $552.
Beneficial Conversion Feature of convertible notes payable	Beneficial Conversion Feature of convertible notes payable The Beneficial Conversion Feature ("BCF") of a convertible note is normally characterized as the convertible portion or feature of certain notes payable that provide a rate of conversion that is below market value or in-the-money when issued. The Company records a BCF related to the issuance of a convertible note when issued and also records the estimated fair value of any warrants issued with those convertible notes. Beneficial conversion features that are contingent upon the occurrence of a future event are recorded upon the occurrence of the event. The BCF of a convertible note is measured by allocating a portion of the note's proceeds to the warrants, if applicable, and as a reduction of the carrying amount of the convertible note equal to the intrinsic value of the conversion feature, both of which are credited to additional paid-in-capital. The value of the proceeds received from a convertible note is then allocated between the conversion features and warrants on an allocated fair value basis. The allocated fair value is recorded in the financial statements as a debt discount (premium) from the face amount of the note and such discount is amortized over the expected term of the convertible note (or to the conversion date of the note, if sooner) and is charged to interest expense.
Net loss per share	Net loss per share Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. No fully diluted loss per share is presented, because it would be anti-dilutive.
Revenue recognition	Revenue recognition The Company recognizes revenue when control is transferred to the customer. For products sold through direct sales representatives, control is transferred upon shipment or upon delivery, based on the contract terms and legal requirements. Payment terms vary depending on the country of sale, type of customer, and type of product. If a contract contains more than one performance obligation, the transaction price is allocated to each performance obligation based on relative standalone selling price. Shipping and handling is treated as a fulfillment activity rather than a promised service, and therefore, is not considered a performance obligation. Taxes assessed by a governmental authority that are both imposed on, and concurrent with, a specific revenue producing transaction and collected by the Company from customers (for example, sales, use, value added, and some excise taxes) are not included in revenue. For contracts that have an original duration of one year or less, the Company uses the practical expedient applicable to such contracts and does not adjust the transaction price for the time value of money. We are not currently selling or marketing any products, as our product is in late stage development and FDA clearance to market the product will be required in order to sell in the United States.

2. Restatement for Correction_2

2. Restatement for Correction of an Error (Tables)	12 Months Ended
	Jul. 31, 2019
Accounting Changes and Error Corrections [Abstract]
Restatement tables	Balance Sheet As Previously Reported Adjustments As Restated Assets Current assets: Cash and cash equivalents $ 167,095 $ – $ 167,095 Prepaid expenses 302,833 – 302,833 Loan receivable 50,000 – 50,000 Total current assets 519,928 – 519,928 Property and equipment, net 1,517 – 1,517 Intangible assets - patents & license distribution rights 23,139,570 (23,124,570 ) 15,000 Total assets $ 23,661,015 $ (23,124,570 ) $ 536,445 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 47,743 $ – $ 47,743 Accrued wages 297,547 – 297,547 Contingent liability 144,000 (144,000 ) – Notes payable, including accrued interest 784,913 – 784,913 Total liabilities 1,274,203 (144,000 ) 1,130,203 Stockholders' equity (deficiency): Preferred stock, $.001 par value; 100,000,000 shares authorized, no shares issued or outstanding – – – Common stock, $.001 par value; 500,000,000 shares authorized with 86,990,400 and 61,414,000 issued and outstanding 86,990 – 86,990 Additional paid-in capital 23,821,124 – 23,821,124 Deficit (1,521,302 ) (22,980,570 ) (24,501,872 ) Total stockholders’ equity (deficiency) 22,386,812 (22,980,570 ) (593,758 ) Total liabilities and stockholders’ equity (deficiency) $ 23,661,015 $ (23,124,570 ) $ 536,445 Odyssey Group International, Inc. Statements of Operations July 31, 2019 As Previously Reported Adjustments As Restated Revenues – – – Costs of goods sold – – – Gross profit – – – General and administrative expense $ 378,143 $ 22,980,570 $ 23,358,713 Loss from operations (378,143 ) (22,980,570 ) (23,358,713 ) Interest expense (70,282 ) – (70,282 ) Net loss $ (448,425 ) $ (22,980,570 ) $ (23,428,995 ) Basic net loss per share: (0.01 ) $ (0.33 ) $ (0.34 ) Weighted average number of shares $ 69,898,436 69,898,436 69,898,436 Odyssey Group International, Inc. Statements of Stockholders’ Equity (Deficiency) For the Years Ended July 31, 2019 and 2018 Common Stock Additional Paid-In Total Equity Shares Dollars Capital Deficit (Deficiency) Balances July 31, 2017 114,839,600 $ 114,840 $ 55,060 $ (589,762 ) $ (419,862 ) Debt converted to common stock 1,574,400 1,574 32,026 – 33,600 Common stock issued for services 5,000,000 5,000 45,000 – 50,000 Common stock restructure (60,000,000 ) (60,000 ) 60,000 – – Net loss – – – (483,115 ) (483,115 ) Balances July 31, 2018 61,414,000 $ 61,414 $ 192,086 $ (1,072,877 ) $ (819,377 ) Note payable converted to common stock 2,531,400 2,531 22,783 – 25,314 Common stock issued for services 321,000 321 331,929 – 332,250 Common stock issued for compensation 4,720,000 4,720 67,280 – 72,000 Common stock issued for acquisition of in-process research and development 18,004,000 18,004 22,486,996 – 22,505,000 Common stock options issued for acquisition of in-process research and development – – 506,400 – 506,400 Warrants issued in connection with convertible notes – – 13,075 – 13,075 Beneficial conversion feature related to convertible notes – – 200,575 – 200,575 Net loss - (Restated) – – – (23,428,995 ) (23,428,995 ) Balances July 31, 2019 (Restated) 86,990,400 $ 86,990 $ 23,821,124 $ (24,501,872 ) $ (593,758 ) Odyssey Group International, Inc. Statements of Cash Flows Year Ended July 31, 2019 As Previously Reported Adjustments As Restated Operating activities Net loss $ (448,425 ) $ (22,980,570 ) $ (23,428,995 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization expense 41,381 (30,830 ) 10,551 Common stock for in-process research and development – 23,011,400 23,011,400 Stock based payment expense for consulting and compensation 101,417 – 101,417 Debt discount 408 – 408 Changes in operating assets and liabilities: Increase in accounts payable 21,053 – 21,053 Increase in accrued wages 109,047 – 109,047 Increase in accrued interest 70,282 – 70,282 Net cash used in operating activities (104,837 ) – (104,837 ) Financing activities Proceeds from note payable 271,542 – 271,542 Net cash provided by financing activities 271,542 – 271,542 Net change in cash and cash equivalents 166,705 – 166,705 Cash and cash equivalents, beginning of year 390 – 390 Cash and cash equivalents, end of year $ 167,095 – $ 167,095 Noncash Investing and Financing Activities Common stock issued for acquisition of intangible assets $ 22,505,000 $ (22,505,000 ) – Common stock issued for consulting services 332,250 – 332,250 Beneficial conversion feature related to convertible notes 213,650 – 332,250 Contingency liability related to acquisition of intangible assets 144,000 (144,000 ) – Debt converted to common stock 25,314 – 23,314

2. Summary of Significant Accou

2. Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Jul. 31, 2019	Jul. 31, 2018
Accounting Policies [Abstract]
Depreciation expense	$ 552	$ 552

6. Notes Payable (Details Narra

6. Notes Payable (Details Narrative)	12 Months Ended
	Jul. 31, 2019USD ($)$ / shares
Note Payable [Member]
Maturity date	Jan. 31, 2020
Interest rate	12.50%
Conversion price per share | $ / shares	$ 0.01
Convertible note payable outstanding	$ 747,608
Convertible Notes [Member]
Interest rate	7.00%
Conversion price per share | $ / shares	$ 0.01
Convertible note payable outstanding	$ 37,305
Beneficial conversion feature	$ 213,650

8. Common Stock (Details Narrat

8. Common Stock (Details Narrative) - USD ($)	3 Months Ended	4 Months Ended	5 Months Ended	6 Months Ended	11 Months Ended	12 Months Ended
	Apr. 30, 2019	May 22, 2019	Jan. 09, 2019	Jul. 31, 2019	Jun. 27, 2019	Jul. 31, 2019	Jul. 31, 2018
Stock granted for compensation, shares						72,000
Share based compensation						$ 101,417	$ 0
Amount per share				$ 0.001		$ 0.001	$ .001
Employee 1 [Member]
Stock granted for compensation, shares		10,000
Employee 2 [Member]
Stock granted for compensation, shares		10,000
Founding Stockholders [Member]
Stock returned, shares returned							60,000,000
J. Michael Redmond [Member]
Stock granted for compensation, shares						4,700,000
Share based compensation						$ 47,000
Green Energy Alternatives [Member]
Stock granted for compensation, shares						5,300,000
Vivakor [Member]
Debt converted, amount converted			$ 25,314
Debt converted, shares issued			2,531,400
Consulting Services [Member]
Stock granted for compensation, shares	100,000			305,000
Vanlandingham [Member] | Acquisition of Patent [Member]
Stock granted for acquisition of intangible assets					984,000
Vanlandingham [Member] | Director Compensation [Member]
Stock granted for compensation, shares					20,000
De Luca Agreement [Member] | Patent and Intellectual Property [Member]
Stock granted for compensation, shares					20,000
Stock granted for acquisition of intangible assets					600,000

9. Stock Based Compensation (De

9. Stock Based Compensation (Details Narrative) - Options [Member] - J. Michael Redmond [Member]	12 Months Ended
	Jul. 31, 2019$ / sharesshares
Options granted | shares	15,000,000
Fair value options granted per share | $ / shares	$ 0.25

10. Income Taxes (Details Narra

10. Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Jul. 31, 2019	Jul. 31, 2018
Income Tax Disclosure [Abstract]
Net deferred tax assets	$ 0	$ 0
Net operating loss carryforwards expiration date	Dec. 31, 2035
Effective tax rate	21.00%	21.00%

11. Going Concern (Details Narr

11. Going Concern (Details Narrative) - USD ($)	Jul. 31, 2019	Jul. 31, 2018
Risks and Uncertainties [Abstract]
Operating deficit	$ (24,501,872)	$ (1,072,877)

12. Related Party Transactions

12. Related Party Transactions (Details Narrative) - shares	Jul. 31, 2019	Jul. 31, 2018
Common stock owned	86,990,400	61,414,000
Green Energy Alternatives [Member]
Common stock owned	5,300,000	5,300,000